Ospemifene’s effect more comprehensive than its FDA indication
November 24, 2014|Ob.Gyn. News
Author and Disclosure Information
AT THE NAMS 2014 ANNUAL MEETING
Other symptoms such as irritation, itching, and painful urination also were improved, but did not achieve statistical significance in either study.
Given the data seen in this context, Dr. Constantine concluded that ospemifene’s limited indication was predicated more on study constructs than on failure to provide relief from other moderate to severe symptoms.
Dr. Constantine is a paid consultant and board member for Shionogi, the maker of Osphena.
On Twitter @whitneymcknight
